{
    "clinical_study": {
        "@rank": "166636", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Active Comparator", 
                "description": "Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated only with fluconazole."
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Active Comparator", 
                "description": "Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated with both fluconazole and Ibuprofen."
            }, 
            {
                "arm_group_label": "3", 
                "arm_group_type": "Active Comparator", 
                "description": "Premature newborn infants with Gestational Age 27+0 to 36+6 who are treated only with ibuprofen."
            }, 
            {
                "arm_group_label": "4", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Premature newborn infants with Gestational Age 27+0 to 36+6 and fullterm infants who are not treated either with fluconazole or ibuprofen."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate pharmacological interventions between fluconazole and ibuprofen\n      when they are given to premature newborn babys. This in order to find out if the drugs are\n      influencing each other when they are given at the same time. The study is meant to find out\n      if there are reasons to adjust the dose when fluconazole and ibuprofen are given together."
        }, 
        "brief_title": "Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ductus Arteriosis, Patent", 
            "Bacterial Infections and Mycoses"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Mycoses"
            ]
        }, 
        "detailed_description": {
            "textblock": "To evaluate the effect of fluconazole and/or ibuprofen on the urinary excretion of two\n      vasoactive arachidonic acid products,  thromboxane A2 (TXA2) and prostacycline (PGI2), in\n      newborn infants treated with one or both of these drugs because of fungal infection\n      prophylaxis and/or patent ductus arteriosis (PDA), respectively, as measurement of the\n      possible interactions between these drugs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Newborn infants in need of prophylaxis with fluconazole according to clinical\n             routines and/or clinical indication for treatment of Patent Ductus Arteriosis (PDA),\n             or newborn infants who are not treated with either fluconazole or ibuprofen according\n             to the following study groups:\n\n             1.1  Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are\n             treated only with fluconazole.\n\n             1.2 Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated\n             with both fluconazole and Ibuprofen.\n\n             1.3 Premature newborn infants with Gestational Age 27+0 to 36+6 who are treated only\n             with ibuprofen.\n\n             1.4 Premature newborn infants with Gestational Age  27+0 to 36+6 and fullterm infants\n             who are not treated either with fluconazole or ibuprofen.\n\n          2. Parents that are in command of the Swedish language and capable of understanding the\n             study plan\n\n          3. Informed written parental consent\n\n        Exclusion Criteria:\n\n          1. Infants who need treatment with other drugs that are metabolised by enzyme Cytochrome\n             (CYP2C9) (such as phenytoin, sulphamethoxazole, fluvastatin, sildenafil, losartan,\n             irbesartan, torsemide, tienilic acid), or any other enzyme involved in the metabolism\n             of fluconazole and or NSAIDs, or treatment with drugs that interact with NSAIDs at\n             the cyclooxygenase level, or interact with the vasal effects of the metabolic\n             products of the cyclooxygenase.\n\n          2. Infants without possibility to conceive the objectives and implications of the study\n             in the opinion of the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "42 Weeks", 
            "minimum_age": "23 Weeks"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079298", 
            "org_study_id": "EudraCT number: 2013-003611-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "intervention_name": "Treatment with fluconazole.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "intervention_name": "2. Treatment with both fluconazole and Ibuprofen.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3", 
                "intervention_name": "3. Treatment with ibuprofen.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4", 
                "intervention_name": "4. No treatment with either fluconazole nor ibuprofen.", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Inflammatory Agents", 
                "Ibuprofen", 
                "Anti-Inflammatory Agents, Non-Steroidal", 
                "Fluconazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "yinghua.li@karolinska.se", 
                "last_name": "Yinghua Li, MD, PhD", 
                "phone": "\u00b4+46 8 51778331"
            }, 
            "facility": {
                "address": {
                    "city": "Stockholm", 
                    "country": "Sweden", 
                    "zip": "171 76"
                }, 
                "name": "Neonatal Intensive Care Unit, Karolinska University Hopsital"
            }, 
            "investigator": {
                "last_name": "Yinghua Li, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "4", 
        "official_title": "Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics", 
        "overall_contact": {
            "email": "anders.rane@ki.se", 
            "last_name": "Anders Rane, MD Prof.", 
            "phone": "+46 8 585 810 51"
        }, 
        "overall_contact_backup": {
            "email": "yinghua.li@karolinska.se", 
            "last_name": "Yinghua Li, MD, PhD", 
            "phone": "+46 8 517 78331"
        }, 
        "overall_official": {
            "affiliation": "Karolinska Institutet", 
            "last_name": "Anders Rane, Prof. MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Sweden: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the effect of fluconazole and/or ibuprofen on the urinary excretion of two vasoactive arachidonic acid products, thromboxane A2 (TXA2) and prostacycline (PGI2), in newborn infants treated with one or both of these drugs for fungal infection prophylaxis and/or patent ductus arteriosis (PDA), respectively.", 
            "measure": "Urinary concentrations of prostacycline (PGI2) and thromboxane A2 (TxA2) measured in picogram/milliliter.", 
            "safety_issue": "Yes", 
            "time_frame": "5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079298"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska Institutet", 
            "investigator_full_name": "Anders Rane, MD, PhD, Senior professor", 
            "investigator_title": "Senior professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate if genetic variability in the enzyme Cytochrome (P4502C) influence the urinary excretion of two vasoactive arachidonic acid products: thromboxane A2 (TXA2) and prostacycline (PGI2) in newborn infants treated with fluconazole and/or ibuprofen.", 
                "measure": "Concentration of thromboxane A2 (TXA2) and prostacycline (PGI2) in relation to genetic variation of the enzymes of the Cytochrome (P4502C) family.", 
                "safety_issue": "Yes", 
                "time_frame": "5 days"
            }, 
            {
                "description": "To evaluate safety of fluconazole and ibuprofen given separately or in combination to newborn infants with clinical indication for treatment with these drugs.", 
                "measure": "Number of and type of Adverse Drug Reactions", 
                "safety_issue": "Yes", 
                "time_frame": "5 days"
            }
        ], 
        "source": "Karolinska Institutet", 
        "sponsors": {
            "collaborator": {
                "agency": "Karolinska University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Anders Rane, MD, PhD, Senior professor", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}